Physician profile
David M Lima
NPI 1104810357
$1,477.58
in general payments reported to CMS, 2019-2025
21 companies · $62.68 in 2025
The $62.68 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $135 · 2022: $219 · 2023: $352 · 2024: $200 · 2025: $62.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $426.03 | 2019-2024 | Slynd |
| Abbvie INC. | $373.34 | 2019-2023 | |
| Astellas Pharma US INC | $79.82 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $70.93 | 2019-2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $49.37 | 2019-2023 | |
| Exact Sciences Corporation | $47.97 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $47.00 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $46.75 | 2023-2024 | |
| Lupin INC. | $40.76 | 2019-2020 | |
| Millicent US INC | $40.66 | 2019-2025 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $40.21 | 2019-2020 | |
| Therapeuticsmd, INC. | $36.59 | 2019-2020 | |
| Pfizer INC. | $33.98 | 2023 | |
| Duchesnay USA Incorporated | $21.75 | 2019 | |
| Sage Therapeutics, LLC | $21.36 | 2025 | Zurzuvae |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $20.02 | 2019 | |
| Sumitomo Pharma America, INC. | $18.83 | 2024 | Myfembree |
| Organon LLC | $17.00 | 2022 | |
| Myovant Sciences INC. | $16.54 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $15.43 | 2023 | Vivjoa |
| Evofem Biosciences, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.